Is the presence of antiphospholipid antibodies a poor prognostic factor for patients with hemolysis, elevated liver enzymes, and low platelet count syndrome?


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
10 2021
Historique:
received: 23 01 2021
revised: 15 03 2021
accepted: 30 03 2021
pubmed: 5 4 2021
medline: 26 10 2021
entrez: 4 4 2021
Statut: ppublish

Résumé

The characteristics of antiphospholipid syndrome-associated hemolysis, elevated liver enzymes, and low platelet count syndrome are poorly described, likely because of the low frequency of this combination of syndromes. This study aimed to compare the characteristics and prognosis of hemolysis, elevated liver enzymes, and low platelet count syndrome in patients with and without antiphospholipid syndrome. In this multicenter, case-control study, adult women diagnosed with hemolysis, elevated liver enzymes, and low platelet count syndrome before 34 weeks' gestation and who were also tested for antiphospholipid antibodies according to international diagnostic recommendations were included. Cases labeled "HELLP-APS+" were defined as patients who fulfilled the international classification criteria for antiphospholipid syndrome; they were retrospectively recruited by screening the 672 patients with antiphospholipid syndrome in our antiphospholipid syndrome database. Control cases labeled "HELLP-APS-" were defined as patients who did not fulfill the criteria for antiphospholipid syndrome; they were retrospectively recruited from our hospital admission database. Overall, 71 patients were included (mean age, 30±5 years), with 23 patients in the hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome group and 48 patients in the hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome group. The live birth rate was significantly lower for patients with hemolysis, elevated liver enzymes, and low platelet count with antiphospholipid syndrome than for those with hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome (43.5% vs 89.4%; P<.001). The patients with hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome gave birth prematurely more often than the patients without antiphospholipid syndrome (24 weeks' gestation; 22.0-28.0 weeks vs 30 weeks' gestation; 27.0-33.0 weeks; P<.001). Among the patients with hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome, 39% required an induced abortion owing to hemolysis, elevated liver enzymes, and low platelet count syndrome severity vs 8.5% of the patients with hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome (P=.006). The intensive care unit admission rate was 61.9% in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome, which was significantly higher than the rate of 27.7% in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome (P=.007). None of the mothers died. Our results suggest that the presence of antiphospholipid syndrome is a poor prognostic factor for both the mother and fetus in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.

Sections du résumé

BACKGROUND
The characteristics of antiphospholipid syndrome-associated hemolysis, elevated liver enzymes, and low platelet count syndrome are poorly described, likely because of the low frequency of this combination of syndromes.
OBJECTIVE
This study aimed to compare the characteristics and prognosis of hemolysis, elevated liver enzymes, and low platelet count syndrome in patients with and without antiphospholipid syndrome.
STUDY DESIGN
In this multicenter, case-control study, adult women diagnosed with hemolysis, elevated liver enzymes, and low platelet count syndrome before 34 weeks' gestation and who were also tested for antiphospholipid antibodies according to international diagnostic recommendations were included. Cases labeled "HELLP-APS+" were defined as patients who fulfilled the international classification criteria for antiphospholipid syndrome; they were retrospectively recruited by screening the 672 patients with antiphospholipid syndrome in our antiphospholipid syndrome database. Control cases labeled "HELLP-APS-" were defined as patients who did not fulfill the criteria for antiphospholipid syndrome; they were retrospectively recruited from our hospital admission database.
RESULTS
Overall, 71 patients were included (mean age, 30±5 years), with 23 patients in the hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome group and 48 patients in the hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome group. The live birth rate was significantly lower for patients with hemolysis, elevated liver enzymes, and low platelet count with antiphospholipid syndrome than for those with hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome (43.5% vs 89.4%; P<.001). The patients with hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome gave birth prematurely more often than the patients without antiphospholipid syndrome (24 weeks' gestation; 22.0-28.0 weeks vs 30 weeks' gestation; 27.0-33.0 weeks; P<.001). Among the patients with hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome, 39% required an induced abortion owing to hemolysis, elevated liver enzymes, and low platelet count syndrome severity vs 8.5% of the patients with hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome (P=.006). The intensive care unit admission rate was 61.9% in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome with antiphospholipid syndrome, which was significantly higher than the rate of 27.7% in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome without antiphospholipid syndrome (P=.007). None of the mothers died.
CONCLUSION
Our results suggest that the presence of antiphospholipid syndrome is a poor prognostic factor for both the mother and fetus in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.

Identifiants

pubmed: 33812811
pii: S0002-9378(21)00219-2
doi: 10.1016/j.ajog.2021.03.039
pii:
doi:

Substances chimiques

Antibodies, Antiphospholipid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

432.e1-432.e7

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Mathilde Pécourt (M)

Vascular Medicine Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France. Electronic address: mathilde.pecourt@gmail.com.

Cécile Yelnik (C)

Internal Medicine and Clinical Immunology Department, Reference Center for Rare Systemic Autoimminue Diseases of North and Northwest France (CeRAINO), European Reference Network on Rare Connective Tissues and Musculoskeletal Diseases (ReCONNECT), Centre Hospitalier Universitaire de Lille, Lille, France.

Louise Ghesquiere (L)

Gynecology-Obstetrics Department, Centre Hospitalier Universitaire de Lille, Lille, France.

Élodie Drumez (É)

ULR 2694 Metrics Evaluation of Health Techonologies and Medical Practices Unit, Biostatistics Department, Centre Hospitalier Universitaire de Lille, Lille, France.

Émeline Cailliau (É)

ULR 2694 Metrics Evaluation of Health Techonologies and Medical Practices Unit, Biostatistics Department, Centre Hospitalier Universitaire de Lille, Lille, France.

Éric Hachulla (É)

Internal Medicine and Clinical Immunology Department, Reference Center for Rare Systemic Autoimminue Diseases of North and Northwest France (CeRAINO), European Reference Network on Rare Connective Tissues and Musculoskeletal Diseases (ReCONNECT), Centre Hospitalier Universitaire de Lille, Lille, France.

Véronique Debarge (V)

Gynecology-Obstetrics Department, Centre Hospitalier Universitaire de Lille, Lille, France.

Nathalie Morel (N)

INSERM U1153, Internal Medicine Service, Reference Center for Rare Systemic Autoimminue Diseases, Hôpital Cochin, Université de Paris, Paris, France.

Véronique Le Guern (V)

INSERM U1153, Internal Medicine Service, Reference Center for Rare Systemic Autoimminue Diseases, Hôpital Cochin, Université de Paris, Paris, France.

Charles Garabedian (C)

Gynecology-Obstetrics Department, Centre Hospitalier Universitaire de Lille, Lille, France.

Nathalie Costedoat-Chalumeau (N)

INSERM U1153, Internal Medicine Service, Reference Center for Rare Systemic Autoimminue Diseases, Hôpital Cochin, Université de Paris, Paris, France.

Marc Lambert (M)

Internal Medicine and Clinical Immunology Department, Reference Center for Rare Systemic Autoimminue Diseases of North and Northwest France (CeRAINO), European Reference Network on Rare Connective Tissues and Musculoskeletal Diseases (ReCONNECT), Centre Hospitalier Universitaire de Lille, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH